Medical Research Centers

04 Aug

Posted at 16:45h in Author Interviews, Columbia, Environmental Risks

MedicalResearch.com Interview with:

Ellen B. Bannon, MPH

PhD Student, Department of Environmental Health Sciences

Columbia Mailman School of Public Health

[caption id="attachment_75435" align="alignleft" width="200"]Ellen Bannon Ellen Bannon[/caption]

MedicalResearch.com: What is the background for this study? What are the main findings?

Ms. Bannon: Lithium is an increasingly important element thanks to its use in rechargeable batteries and the green energy transition. However, we know relatively little about how people are exposed to lithium in their everyday lives. In many areas of the United States, lithium is present in groundwater and drinking water due to natural weathering processes, but few studies have quantified human exposure to lithium. Our study addresses this gap by measuring lithium in household tap water and urine samples from participants in the Strong Heart Family Study across Tribal communities in Arizona, Oklahoma, North Dakota, and South Dakota. This approach parallels earlier work examining other naturally occurring groundwater contaminants — a framework explored in this MedicalResearch.com overview of how naturally occurring contaminants in drinking water affect human health even at low exposure levels.

Our main findings were threefold. First, household drinking water samples frequently exceeded the United States Geological Survey health-based screening level of 10 µg/L, with 100% and 93% of samples exceeding the screening level in Arizona and North Dakota/South Dakota, respectively. Both water and urine lithium levels were highest in Arizona and lowest in Oklahoma. Second, household drinking water is an important contributor to internal lithium exposure — water lithium concentrations were significantly associated with urinary lithium levels and explained approximately 29% of variation in urinary lithium. Finally, urinary lithium levels remained stable between our urine sampling periods (2006–2009 and 2022–2024), suggesting that environmental lithium exposure has remained persistent over time.

03 Aug

Posted at 21:33h in Author Interviews, Cancer Research, Wistar

MedicalResearch.com Interview with:

Aidan Cole, PhD

Postdoctoral Researcher, Aird Lab

The Wistar Institute, Philadelphia

[caption id="attachment_75414" align="alignleft" width="150"]Aidan Cole, PhD Aidan Cole, PhD[/caption]

MedicalResearch.com: What is the background for this study? What are the main findings?

Dr. Cole: Our lab was interested in what happens in a tumor after chemotherapy treatment when some cells stop proliferating and growing the tumor but are not killed. These are called senescent cells, and they are of particular interest in ovarian cancer because of the prevalence of cancer recurrence and spread after initially responding to treatment.

The biggest finding is we learned how these senescent cells communicate with cancerous cells to get them to loosen their grip on the tumor and spread to other parts of the body. This communication occurs when senescent cells produce a sugar called fructose. For the first time, we've shown that a nutrient can be produced in these senescent cells and used by cancer cells in a way that worsens cancer spread. This builds on research previously covered on MedicalResearch.com exploring how senescence in ovarian cancer cells may contribute to chemotherapy resistance.

24 Jul

Posted at 20:39h in Accidents & Violence, Author Interviews, JAMA, Ophthalmology, UCSD

MedicalResearch.com Interview with:

[caption id="attachment_75222" align="alignleft" width="200"]Dr. Don Kikkawa Dr. Don Kikkawa[/caption]

Don Kikkawa, MD Distinguished Professor, UC San Diego Viterby Family Department of Ophthalmology Chief, Division of Oculofacial Plastic and Reconstructive Surgery Vice-Chairman, Department of Ophthalmology UCSD

 

[caption id="attachment_75223" align="alignleft" width="125"]dr_leo-miller-md Dr. Leo Miller[/caption]

Leo Meller, MD

UC San Diego School of Medicine, Class of 2026

   

MedicalResearch.com: What is the background for this study?

Dr. Kikkawa and Dr. Meller: Hockey can put players at risk for eye injuries because of high-speed pucks, sticks, and close-contact play. While many sports-related eye injuries are preventable, there has been limited national data on the frequency and severity of hockey-related eye injuries across different types of hockey. Our research used 20 years of U.S. emergency department data to better understand these injuries. Similar work examining recreational sport eye injury trends — including our related research covered previously on MedicalResearch.com on serious and preventable eye injuries treated in emergency settings — underscores why population-level surveillance data matters for guiding prevention efforts.

[caption id="attachment_75224" align="aligncenter" width="500"]ice-hockey-ocular-injuries-pexels.jpg Photo by Luke Miller[/caption]

24 Mar

Posted at 23:42h in Alzheimer's - Dementia, Author Interviews, Genetic Research, JAMA, Karolinski Institute
[caption id="attachment_72900" align="alignleft" width="200"]MedicalResearch.com Interview with:Jakob Norgren | PhD, Postdoctoral Researcher Department of Neurobiology, Care Sciences and Society (NVS) | Karolinska Institutet Division of Clinical Geriatrics | Center for Alzheimer Research Huddinge, Sweden Jakob Norgren, Ph.D.[/caption] MedicalResearch.com Interview with: Jakob Norgren | PhD, Postdoctoral Researcher Department of Neurobiology, Care Sciences and Society (NVS) | Karolinska Institutet Division of Clinical Geriatrics | Center for Alzheimer Research Huddinge, Sweden     MedicalResearch.com: What is the background for this study? Response: This study tested the hypothesis that people with APOE 3/4 and 4/4 would have a reduced risk of cognitive decline and dementia with higher meat intake, based on the fact that APOE4 is the evolutionarily oldest variant of the APOE gene and may have arisen during a period when our evolutionary ancestors ate a more animal-based diet.

25 Feb

Posted at 19:14h in Author Interviews, Infections, Nature, NYU/NYMC
[caption id="attachment_72626" align="aligncenter" width="500"]C. auris- CDC image.jpg Candida auris CDC Image[/caption] MedicalResearch.com Interview with: [caption id="attachment_72627" align="alignleft" width="200"]Vishnu Chaturvedi, Ph.D.Professor of Pathology, Microbiology, and Immunology and of Medicine New York Medical College Vishnu Chaturvedi, Ph.D.[/caption] Vishnu Chaturvedi, Ph.D. Professor of Pathology, Microbiology, and Immunology and of Medicine New York Medical College MedicalResearch.com: What is the background for this study? Response: The research was prompted by the rise of Candida auris (C. auris) as a critical fungal pathogen that has caused global outbreaks in healthcare facilities with high mortality rates. C. auris is particularly difficult to control because it can survive on physical surfaces for extended periods. Current diagnostic methods (such as culture-based approaches or mass spectrometry) are often costly, slow, and require complex equipment in centralized laboratories, which delays effective clinical responses. There is an urgent need for rapid tests that can both identify the fungus and measure its level of drug resistance.

20 Feb

Posted at 00:17h in Author Interviews, Melanoma, NYU/NYMC
[caption id="attachment_72519" align="alignleft" width="200"]Pietro Berico, M.Sc., Ph.D.Postdoctoral research fellow Hernando Lab NYU Grossman School of Medicine NYU Langone Health New York, NY 10016 Dr. Berico[/caption] MedicalResearch.com Interview with: Pietro Berico, M.Sc., Ph.D. Postdoctoral research fellow Hernando Lab NYU Grossman School of Medicine NYU Langone Health New York, NY 1001 MedicalResearch.com: What is the background for this study? Response: “Cutaneous melanoma arises under chronic UV irradiation, which selects for aggressive malignant clones. Paradoxically, its high mutational burden also promotes neoantigen formation and robust immune activation. Consequently, melanoma must establish immune evasion mechanisms from the earliest stages of tumor development. The lack of specific genetic mutational patterns linked to immune escape points toward non-mutational mechanisms, such as epigenetic reprogramming.

06 Feb

Posted at 16:38h in Author Interviews, Epidemiology, UCSD
MedicalResearch.com Interview with: [caption id="attachment_72295" align="alignleft" width="150"]Raphael Cuomo Dr. Cuomo[/caption] Raphael E. Cuomo, PhD Professor of Medicine Associate Adjunct Professor, Anesthesiology University of California, San Diego MedicalResearch.com: What is the background for this study? Response: Epidemiology has mostly been built to explain who gets sick, but many of the decisions that matter most happen after diagnosis. Across multiple diseases, relationships that look consistent in prevention studies often do not hold once people already have the disease, and sometimes they even flip. Diagnosis can change patient biology, treatment context, and biases in the data, so we need clearer methods and language for postdiagnosis questions.

18 Jan

Posted at 23:02h in Alzheimer's - Dementia, Author Interviews, Lipids, Vanderbilt
MedicalResearch.com Interview with: [caption id="attachment_72035" align="alignleft" width="200"]Leslie S. Gaynor, PhDClinical Neuropsychologist & Assistant Professor of Medicine Division of Geriatric Medicine Department of Medicine Vanderbilt University Medical Center Nashville, TN 37203 Dr. Gaynor[/caption] Leslie S. Gaynor, PhD Clinical Neuropsychologist & Assistant Professor of Medicine Division of Geriatric Medicine Department of Medicine Vanderbilt University Medical Center Nashville, TN 37203 MedicalResearch.com: What is the background for this study? Response: The US population is rapidly aging, and the oldest members of our population are also the most vulnerable to developing clinical dementia. We are interested in studying older adults ages 80+ who display cognitive resilience despite this increased risk of dementia and actually display exceptional memory performance compared to their same-aged, typically performing peers. These “SuperAgers,”—i.e., 80+-year-old adults with memory performance that is comparable to or surpasses that of adults 20 to 30 years their junior—may hold the key to uncovering genetic factors that predict exceptionally healthy longevity.

25 Dec

Posted at 20:41h in Alzheimer's - Dementia, Author Interviews, Case Western
MedicalResearch.com Interview with: [caption id="attachment_71888" align="alignleft" width="150"]Andrew A. Pieper M.D., Ph.D.Professor, Department of Psychiatry, School of Medicine Professor, Department of Neurosciences Professor, Department of Pathology Investigator, University Hospitals Harrington Discovery Institute, Harrington Discovery Institute Associate Director, Medical Scientist Training Program, School of Medicine Case Western Reserve University, University Hospitals Cleveland Medical Center, and at the Louis Stokes Cleveland VA Medical Center Dr. Pieper[/caption] Andrew A. Pieper M.D., Ph.D. Professor, Department of Psychiatry, School of Medicine Professor, Department of Neurosciences Professor, Department of Pathology Investigator, University Hospitals Harrington Discovery Institute, Harrington Discovery Institute Associate Director, Medical Scientist Training Program, School of Medicine Case Western Reserve University, University Hospitals Cleveland Medical Center, and at the Louis Stokes Cleveland VA Medical Center   MedicalResearch.com: What is the background for this study? Response: NAD+, a central cellular energy and signaling molecule, declines with age throughout the body, including the brain. When NAD+ falls below necessary levels, cells lose their ability to carry out essential maintenance and survival functions. We found that the NAD+ decline is more severe in brains from people with Alzheimer’s disease (AD) and in mouse models of AD, whereas brains of people with AD pathology but preserved cognition show gene-expression patterns consistent with maintained NAD+ homeostasis.

18 Dec

Posted at 22:57h in Author Interviews, Cognitive Issues, Karolinski Institute, Pediatrics
MedicalResearch.com Interview with: Samson Nivins PhD Postdoctoral Researcher, specializing in Perinatal and Pediatric NeurologySamson Nivins PhD Postdoctoral Researcher, specializing in Perinatal and Pediatric Neurology [caption id="attachment_71834" align="alignleft" width="92"]Torkel Klingberg, M.D., Ph.D.Professor of Cognitive Neuroscience at the Stockholm Brain Institute Dr. Klingberg[/caption] Torkel Klingberg, M.D., Ph.D. Professor of Cognitive Neuroscience at the Stockholm Brain Institute Karolinska Institutet, Stockholm Sweden   MedicalResearch.com: What is the background for this study? Response: In the modern era, children’s use of digital media such as watching videos, playing video games, and using social media has increased substantially, often coinciding with a decline in outdoor activities. As many school-aged children now own personal devices, particularly smartphones, it has become easier for them to spend more time on screens than intended. For example, a German survey cited in an EU briefing reported that in 2020, 27% of 8-9-year-olds and 54% of 10-11-year-olds owned a smartphone. In the U.S., ~30% of children own a smartphone by age eight, with many receiving their first device between ages 10 and 11. With growing concerns about screen time, numerous studies have examined its potential consequences and have reported associations between higher screen use and increased ADHD symptoms. However, most of this research has been cross-sectional and has tended to combine different types of digital media such as television, video games, and social media into a single composite measure. This approach may obscure important differences, as various forms of digital media may have distinct effects on ADHD symptoms. To date, relatively few studies have examined the impact of specific types of digital media use on ADHD in a longitudinal framework, and even fewer have accounted for the heritable nature of ADHD. To address these gaps, this U.S. longitudinal study followed children from ages 9-10 to 13-14 years. The study collected repeated measures of daily time spent on specific digital activities, including television and videos, video games, and social media platforms such as TikTok, Instagram, and Facebook. ADHD symptoms specifically inattention and hyperactivity/impulsivity were assessed using parent reports, and analyses adjusted for genetic factors and socioeconomic status.

12 Dec

Posted at 22:10h in Author Interviews, Duke, Leukemia, Nature
MedicalResearch.com Interview with: [caption id="attachment_71759" align="alignleft" width="200"]Dr. Hirschey Dr. Matthew Hirschey[/caption] Matthew Hirschey Ph.D. Associate Professor of Medicine Associate Professor of Cell Biology Associate Professor in Pharmacology and Cancer Biology Member of the Duke Cancer Institute Member of Sarah W. Stedman Nutrition and Metabolism Center Hirschey Lab in the Duke Molecular Physiology Institute, Duke University MedicalResearch.com: What is the background for this study? Would you briefly describe AML and why new therapeutic approaches are needed? Response: Acute myeloid leukemia (AML) is an aggressive blood cancer that begins in the bone marrow and progresses rapidly. While recent advances, particularly the BCL-2 inhibitor venetoclax combined with other agents, have improved outcomes for some patients, many still relapse or don't respond to treatment. The five-year survival rate remains below 30% overall, highlighting an urgent need for new therapeutic strategies. We know that cancer cells rewire their metabolism to fuel rapid growth, and the mitochondria (the cell's powerhouses) play a central role. However, understanding exactly how different metabolic pathways connect and depend on each other has been challenging. We wanted to develop better tools to map these connections and identify new vulnerabilities we could potentially target.

20 Oct

Posted at 15:54h in Author Interviews, Diabetes, Kidney Disease, NYU/NYMC, Weight Research
MedicalResearch.com Interview with: [caption id="attachment_71025" align="alignleft" width="225"]Michael A. Weintraub, MDClinical Assistant Professor Department of Medicine NYU Grossman School of Medicine Dr. Weintraub[/caption] Michael A. Weintraub, MD Clinical Assistant Professor Department of Medicine NYU Grossman School of Medicine MedicalResearch.com: What is the background for this study? Response: The study addresses a critical knowledge gap in diabetes management for dialysis patients. Of the 808,000 people on dialysis in the United States, approximately 60% have diabetes and would be eligible for GLP-1 receptor agonists (GLP-1 RAs). However, these medications have not been well-studied in this population because dialysis dependence is frequently an exclusion criterion in clinical trials.

13 Oct

Posted at 13:41h in Author Interviews, Cancer Research, Dental Research, JAMA, Microbiome, NYU/NYMC, Pancreatic
[caption id="attachment_70956" align="alignleft" width="125"]Jiyoung Ahn, PhDProfessor of Population Health, NYU Grossman School of Medicine Associate Director for Population Science, NYU Perlmutter Cancer Center  NYU Langone Health New York, NY 10016 Dr. Jiyoung Ahn[/caption] MedicalResearch.com Interview with: Jiyoung Ahn, PhD Professor of Population Health, NYU Grossman School of Medicine Associate Director for Population Science, NYU Perlmutter Cancer Center NYU Langone Health New York, NY 10016 MedicalResearch.com: What is the background for this study? Response: About 10 years ago. we reported that people with poor oral health seem to have a greater risk of pancreatic cancer development.  We suspected that this could be due to oral microbiota.  More recently, animal studies, by other groups, showed that bacteria from the mouth can actually travel through saliva into the pancreas. But we didn’t know which exact species of bacteria or fungi might be involved in pancreas cancer development. We therefore conducted this large human study to examine the oral microbiome — including whole bacteria and fungi profiles in the mouth, and to see which bacteria and fungal taxa are associated with subsequent risk of pancreatic cancer development.

06 Oct

Posted at 20:54h in Author Interviews, Autism, Brigham & Women's - Harvard, JAMA

Memantine to Treat Social Impairment in Youths With ASD

MedicalResearch.com Interview with: [caption id="attachment_70898" align="alignleft" width="143"]Gagan Joshi, MDDirector, The Alan & Lorraine Bressler Clinical and Research Program for Autism Spectrum Disorder Associate Director, The Pediatric Psychopharmacology Research Program Associate Program Director, MGH Fellowship in Autism Spectrum Disorder Rovee Endowed Chair in Child Psychiatry Massachusetts General Hospital Associate Professor of Psychiatry Harvard Medical School Dr. Joshi[/caption] Gagan Joshi, MD Director, The Alan & Lorraine Bressler Clinical and Research Program for Autism Spectrum Disorder Associate Director, The Pediatric Psychopharmacology Research Program Associate Program Director, MGH Fellowship in Autism Spectrum Disorder Rovee Endowed Chair in Child Psychiatry Massachusetts General Hospital Associate Professor of Psychiatry Harvard Medical School MedicalResearch.com: What is the background for this study? Response: Intellectually capable individuals with autism often face significant challenges in social functioning, yet pharmacologic treatments specifically targeting social impairments are lacking. Our prior neuroimaging research identified abnormally elevated brain glutamate levels in intellectually capable youth with autism, suggesting a potential neurochemical pathway underlying social difficulties. Based on these findings, we examined the effects of memantine—a glutamate-modulating medication—for the treatment of autism.

23 Sep

Posted at 12:42h in Author Interviews, Blood Pressure - Hypertension, Cancer Research, Stanford
MedicalResearch.com Interview with: [caption id="attachment_70752" align="alignleft" width="150"]Minji Jung PharmD, PhDPostdoctoral Research Fellow in Epidemiology Department of Urology Stanford University Medical Center Stanford, CA Dr. Minji Jung[/caption] Minji Jung PharmD, PhD Postdoctoral Research Fellow in Epidemiology Department of Urology Stanford University Medical Center Stanford, CA MedicalResearch.com: What is the background for this study? Response: Hypertension is a well-established risk factor for kidney cancer, and previous studies have suggested potential links between antihypertensive medications and kidney cancer risk. However, distinguishing the effects of the medications from those of hypertension itself has been challenging. Our meta-analysis systematically evaluated different classes of antihypertensive drugs while accounting for hypertension.

26 Aug

Posted at 10:24h in Author Interviews, Mental Health Research, Race/Ethnic Diversity, University of Pennsylvania
Mental health is shaped by much more than individual experiences or biology. The social and systemic forces that surround a person—including their identity and environment—play a critical role in determining how they access care, the kind of treatment they receive, and their overall likelihood of facing mental health challenges. This is where the concept of intersectionality offers crucial insight. Originally introduced by legal scholar Kimberlé Crenshaw, intersectionality highlights how overlapping social identities—such as race, gender, socioeconomic status, and disability—combine to influence a person’s lived experience. When it comes to mental health, this framework helps us better understand how multiple layers of disadvantage can magnify risks and create barriers to care.

07 Aug

Posted at 11:53h in Author Interviews, Education, Health Care Workers, Menopause, University of Pittsburgh
[caption id="attachment_70198" align="aligncenter" width="500"]Before Starting a Career in Health Source[/caption] Ever watched a nurse steady a patient’s arm during an injection, answer a family’s questions, juggle documentation, and still keep calm—then thought, I could do that? It’s a common spark. Health careers are high-impact, in demand, and offer the kind of work that feels meaningful. But behind the scrubs and steady hands is a world that asks more than most people expect. In this blog, we will share what you need to know before stepping into a health career. Start With the Structure, Not the Aesthetic Everyone sees the outside first—neatly pressed uniforms, digital charts, exam gloves, badges swinging from lanyards. What’s less obvious is the scaffolding beneath. Health work is layered. Each role connects to others, and each tier carries specific responsibilities, training, and legal scope. If you're picturing your future in health, the first thing to understand is where you want to start, how far you want to go, and what that pathway actually involves. Titles aren’t interchangeable. The difference between a nurse who administers medication and one who diagnoses conditions is more than experience—it’s formal licensing, state-defined boundaries, and years of education. This is where questions like LPN vs nurse practitioner become more than trivia. A Licensed Practical Nurse supports care under the supervision of RNs or physicians, usually after completing a year-long program. A Nurse Practitioner, on the other hand, holds a graduate degree, can assess and diagnose independently in many states, and often carries a caseload similar to a primary care provider. Understanding the distinctions early can save years of missteps. Every job in the system matters, but they’re built on different skill sets. If you want flexibility, long-term growth, or eventual autonomy, you need to plan for that at the start—not halfway through your training. This doesn’t mean locking in a decision forever. It means knowing what each credential unlocks, so you can move with purpose, not guesswork.

23 Jul

Posted at 15:57h in Author Interviews, Environmental Risks, NYU/NYMC
MedicalResearch.com Interview with: [caption id="attachment_69606" align="alignleft" width="225"]Dr. George D. Thurston ScD Professor of Medicine and Population Health Director of the Program in Exposure Assessment and Human Health Effects NYU Grossman School of Medicine Division of Environmental Medicine NYC, NY 10010   Prof. Thurston[/caption] Dr. George D. Thurston Professor of Medicine and Population Health NYU Grossman School of Medicine Division of Environmental Medicine NYC, NY 10010   USA MedicalResearch.com: What is the background for this study? What were some of the chemicals released by the coal-coking plant? Response: Pittsburgh has a long history as the nation's principal source of bituminous coal production and home to iron and coke industries since the late 19th century, and is also known as one of the cities with the highest levels of air pollution and most air-pollution related deaths in the US, to date. The Shenango, Inc Coke Plant was one of the significant industrial emission sources in the area before its closure in January 2016. Coal-coking plants like the Shenango plant utilizes a destructive heated distillation process called pyrolysis to volatilize and drive the impurities out of coal and produce coke, a purer product with higher carbon content for use in iron and steel production. From this process, coke plant operations are known to generate high emissions of complex air pollution mixtures into the ambient air, including particulate matter (PM), sulfur dioxide (SO2), nitrogen oxides (NOx), polycyclic organic matter (POMs), volatile compounds (VOCs), and volatilized trace metals such as arsenic, nickel, selenium, lead, and cobalt. Our study examines the changes in respiratory health in the community residing near the Shenango Coke Plant before vs. after its closure,  providing a direct quantification of the health benefits of such fossil-fuel-related air pollution reductions. 

27 Jun

Posted at 03:14h in Author Interviews, Cancer Research, Chemotherapy, Melanoma, NYU/NYMC
MedicalResearch.com Interview with: [caption id="attachment_69251" align="alignleft" width="156"]Tomas Kirchhoff, PhD (corresponding author)Associate ProfessorLaura and Isaac Perlmutter Cancer Center New York University School of Medicine Dr. Kirchhoff[/caption] Tomas Kirchhoff, PhD (corresponding author) Associate ProfessorLaura and Isaac Perlmutter Cancer Center New York University School of Medicine Robert Ferguson PhD Senior Scientist at NYU Langone Medical Center Kelsey Monson, PhD Immuno-Oncology Postdoctoral Researcher Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study? Would you briefly explain how mitochondrial DNA differs from chromosomal DNA? TK: Immune checkpoint blockade has changed the way we treat several cancers, including advanced melanoma. Before these therapies, the treatment options were very limited, but now more than half of patients experience significant tumor shrinkage or disease control. KRM: Despite these advances, many patients still do not respond to treatment. One of the main challenges in cancer medicine today is to find ways to predict which patients will benefit from these therapies before treatment begins. This approach is key to personalizing care and improving outcomes. RF: Mitochondria are small structures inside our cells that produce the energy needed for cells to function. Unlike most of our DNA, mitochondrial DNA is inherited only from the mother. Scientists can categorize this mitochondrial DNA into groups called haplogroups, based on unique variations in the genetic code. These haplogroups can provide insight into how cells produce energy and may affect a person’s health or response to cancer treatment.

30 Apr

Posted at 01:45h in Author Interviews, Cannabis, Colon Cancer, UCSD
MedicalResearch.com Interview with: [caption id="attachment_68230" align="alignleft" width="150"]Raphael E. Cuomo, PhD, MPH, CPH, FRSPHProfessor, School of Medicine University of California, San Diego Dr. Cuomo[/caption] Raphael E. Cuomo, PhD, MPH, CPH, FRSPH Professor, School of Medicine University of California, San Diego MedicalResearch.com: What is the background for this study? Response: Colon cancer remains a leading cause of cancer-related death worldwide. Recent years have seen a substantial increase in cannabis use, but limited research has explored its potential influence on cancer outcomes. We conducted a large-scale retrospective cohort study using real-world clinical data to investigate whether a diagnosis of cannabis use disorder prior to colon cancer diagnosis was associated with survival outcomes.

14 Feb

Posted at 17:01h in Author Interviews, Gender Differences, JAMA, University of Michigan
MedicalResearch.com Interview with: [caption id="attachment_66556" align="alignleft" width="200"]Farrah Madanay, PhDPostdoctoral Research Fellow Center for Bioethics and Social Sciences in Medicine Michigan Medicine University of Michigan Dr. Madanay[/caption] Farrah Madanay, PhD Postdoctoral Research Fellow Center for Bioethics and Social Sciences in Medicine Michigan Medicine University of Michigan MedicalResearch.com: What is the background for this study? Response: Patients are increasingly using online forums to evaluate their physicians, with not only star ratings but also written narrative reviews. These reviews tend to fall into two dimensions: interpersonal manner, which includes comments about the physician’s attitude, behavior, and communication; and technical competence, which includes comments about the physician’s knowledge, skill, and outcomes. These two dimensions are important for patient-centered care and align with research from social psychology. Whereas prior studies have revealed gender differences in workplace assessments and overall star ratings of physicians, little is known about physician gender differences in patients’ online written reviews. We were curious whether physician gender differences were prevalent in patients’ written reviews and consistent across physician specialties, from generalists, like primary care physicians, to proceduralists, like surgeons. We collected physician profile, rating, and review data from one of the largest commercial physician rating and review websites. We focused on physicians from three primary care specialties (family medicine, internal medicine, and pediatrics), and three surgical specialties (general surgery; orthopedic surgery; and cosmetic, plastic, and reconstructive surgery). Our final sample included 345,053 online reviews received by 167,150 U.S. physicians between 2015 and 2020. We used hand-coded reviews to train an advanced natural language processing algorithm to classify all reviews for the presence and valence of patients’ comments of physicians’ interpersonal manner and technical competence. We then conducted multilevel logistic regressions to analyze differences by female or male physician gender in interpersonal manner and technical competence comments and whether those comments were associated with review star ratings.

12 Feb

Posted at 12:38h in Laboratories, Medical Research Centers, Pharmaceutical Companies
[caption id="attachment_66514" align="aligncenter" width="500"]CROs-medical-research-regulatory approvals Photo by Chokniti Khongchum[/caption] Clinical trials are a fundamental part of medical research, ensuring the safety and efficacy of new drugs, medical devices, and treatments. A Clinical Research Organization (CRO) plays a pivotal role in managing and conducting these trials efficiently. From regulatory compliance to data management, CROs provide expertise that helps sponsors navigate the complexities of clinical research.

What is a Clinical Trials CRO?

A Clinical Research Organization (CRO) is a specialized service provider that assists pharmaceutical companies, biotech firms, and medical device manufacturers in conducting clinical trials. These organizations offer comprehensive services, including study design, patient recruitment, monitoring, regulatory compliance, data collection, and statistical analysis. CROs streamline the clinical trial process, reducing time and costs while ensuring compliance with regulatory authorities such as the FDA and EMA.

Key Services Offered by Clinical Trials CROs

  1. Protocol Development – Designing a scientifically sound and regulatory-compliant study protocol.
  2. Regulatory Compliance – Ensuring adherence to FDA, EMA, and other global regulatory requirements.
  3. Patient Recruitment and Management – Identifying and enrolling eligible patients for clinical trials.
  4. Site Selection and Monitoring – Identifying qualified research sites and ensuring compliance with Good Clinical Practice (GCP).
  5. Data Management and Biostatistics – Collecting, analyzing, and interpreting trial data.
  6. Safety Monitoring – Assessing adverse events and ensuring patient safety throughout the trial.
  7. Quality Assurance – Conducting audits and inspections to maintain data integrity and protocol adherence.
  8. Medical Writing and Reporting – Preparing regulatory submissions, study reports, and scientific publications.

30 Jan

Posted at 01:15h in Author Interviews, Cannabis, JAMA, Pediatrics, UCSD
MedicalResearch.com Interview with: [caption id="attachment_66243" align="alignleft" width="150"]John Bellettiere, PhDAssistant Adjunct Professor Herbert Wertheim School of Public Health & Human Longevity Science University of California, San Diego Dr. Bellettiere[/caption] John Bellettiere, PhD Assistant Adjunct Professor Herbert Wertheim School of Public Health & Human Longevity Science University of California, San Diego MedicalResearch.com: What is the background for this study? Response:  Smoking is the most common method of cannabis use and generates harmful emissions.  Cannabis is often smoked indoors, which exposes non-smokers, including children, to these emissions. Our research analyzed in-home cannabis smoking practices to determine if there is an association between this behavior and the detection of cannabis biomarkers in children.

24 Dec

Posted at 23:17h in Author Interviews, Cancer Research, Lymphoma, Nutrition, University of Pennsylvania
MedicalResearch.com Interview with: [caption id="attachment_65650" align="alignleft" width="200"]Shan Liu, PhD, Postdoctoral fellowPerelman School of Medicine University of Pennsylvania Dr. Shan Liu[/caption] Shan Liu, PhD, Postdoctoral fellow Perelman School of Medicine University of Pennsylvania MedicalResearch.com: What is the background for this study? Response: Our study provides evidence that the efficacy of CAR T cell immunotherapies can be influenced by an important lifestyle factor: diet.   MedicalResearch.com: What are the main findings? Response:  Our study found that a ketogenic diet can enhance CAR T cell function through its metabolite, β-Hydroxybutyrate (BHB). Importantly, instead of altering the diet, providing BHB via oral supplementation in our preclinical model is sufficient to improve the anti-tumor function of CAR T cells. However, it's important to note that we’re still in the early stages, and we’re not yet recommending any dietary changes or supplements for patients.

05 Dec

Posted at 13:44h in Author Interviews, Cancer Research, NEJM, NIH, OBGYNE
MedicalResearch.com Interview with: [caption id="attachment_65321" align="alignleft" width="92"]Diana W. Bianchi, M.D.Senior Investigator Center for Precision Health Research Director, Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health Dr. Bianchi[/caption] Diana W. Bianchi, M.D. Senior Investigator Center for Precision Health Research Director, Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health MedicalResearch.com: What is the background for this study? Response: The ability of prenatal cell-free DNA (cfDNA) sequencing to incidentally detect maternal cancers has been demonstrated by several retrospective studies from commercial or national laboratories. However, there are no standardized approaches to the identification and medical management of prenatal screening results that might indicate a maternal cancer. We sought to prospectively identify DNA sequencing patterns and other biomarkers that could distinguish which women with nonreportable or unusual cfDNA sequencing results had cancer and to determine the best approach for diagnostic work-up of pregnant people who receive these results.

31 Oct

Posted at 22:15h in Author Interviews, Health Care Systems, JAMA, Pharmacology, University of Pittsburgh
MedicalResearch.com Interview with: [caption id="attachment_64457" align="alignleft" width="200"]Dr. Katie Suda Dr. Suda[/caption] Katie J. Suda, PharmD, M.S., FCCP Professor of medicine with tenure Associate Director, Center for Pharmaceutical Policy and Prescribing University of Pittsburgh School of Medicine MedicalResearch.com: What is the background for this study? Response: Our pharmaceutical supply chain is global where the manufacturing process for one drug may occur in multiple countries. Sometimes there are breakdowns in the pharmaceutical supply chain which may threaten access to medicines. Breakdowns in the supply chain occur for medicines manufactured in the U.S. and by international partners. While breakdowns in the supply chain occur for hundreds of drugs each year, not all result in a decrease in available supply (a “drug shortage”) because of action taken by manufacturers, pharmacies and drug regulators (e.g., the U.S. Food and Drug Administration [FDA]). Drug shortages are a critical concern to public health as pharmacies, clinicians, and patients struggle to identify safe and effective alternatives. In addition, drug shortages have been associated with adverse patient outcomes and medication safety events. Recently, drug shortages have gotten worse with shortages occurring with increasing frequency and lasting longer. There has also been a shift in the types of medicines in shortage from drugs primarily used in hospitals, such as injectables, to oral medicines frequently used to manage outpatient conditions. Countries have different regulatory authority and policy which may impact how drug supply chain breakdowns result in drug shortages. We wanted to know if there are differences between the U.S. and Canada in the frequency that national drug shortages occur after supply chain breakdowns are reported in both countries. Canada is a good comparator to the U.S. because Canada has similar drug regulatory standards and manufacturing inspections. Prescription drug coverage is also similar for the two countries where half of prescriptions are reimbursed through public insurance and half through private insurance and out-of-pocket.

27 Oct

Posted at 21:14h in Author Interviews, Mental Health Research, University of Michigan
MedicalResearch.com Interview with: Daniel J. Kruger, PhD University of Michigan MedicalResearch.com: What is the background for this study? Response: A team of researchers from the University of Michigan and University at Buffalo teamed up with psychedelic advocates and therapists to document some of the challenges with psychedelics. They surveyed over a thousand psychedelic users about their adverse experiences and the experiences they have heard from others. Most reported being frightened, sadness, loneliness, and feeling their body tremble or shake at times. Some people experienced panic, paranoia, felt that they are dead, or that the state they were in would last forever. One in ten participants had adverse physical reactions.  For most people having these experiences, they are rare or happen sometimes, but they are still significant. Most of the people that experienced a severe adverse event did not have guidance from someone who was knowledgeable about psychedelics. A small portion of participants knew about an incident of inappropriate sexual contact by a psychedelic sitter, guide, or practitioner, the perpetrators were mostly underground guides and friends or acquaintances.

15 Oct

Posted at 10:55h in Alzheimer's - Dementia, Author Interviews, Cost of Health Care, Medicare, UCLA
MedicalResearch.com Interview with: [caption id="attachment_64014" align="alignleft" width="150"]Frank F. Zhou  |  he/himMD Candidate, Class of 2025 David Geffen School of Medicine at UCLA Frank F Zhou[/caption] Frank F. Zhou  |  he/him MD Candidate, Class of 2025 David Geffen School of Medicine at UCLA MedicalResearch.com: What is the background for this study? What is Lecanemab used for?  How is it given to patients? Response: Lecanemab is a new infusion therapy for Alzheimer's disease. Its dosing is based on each patient's body weight (10 mg/kg every two weeks), but the drug is only available in 500 mg and 200 mg single-use vials, meaning that any leftover drug in vials must be thrown away. Given that lecanemab is expected to cost Medicare billions of dollars each year, we hypothesized that discarded drug could result in significant wasteful spending.